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Abstract
Background: Upon IgE-mediated activation, mast cells (MC) exocytose their cytoplasmic secretory granules and release a
variety of bioactive substances that trigger inflammatory responses. Polyamines mediate numerous cellular and
physiological functions. We report here that MCs express antizyme inhibitor 2 (AZIN2), an activator of polyamine
biosynthesis, previously reported to be exclusively expressed in the brain and testis. We have investigated the intracellular
localization of AZIN2 both in resting and activated MCs. In addition, we have examined the functional role of polyamines,
downstream effectors of AZIN2, as potential regulators of MC activity.
Methodology/Principal Findings: Immunostainings show that AZIN2 is expressed in primary and neoplastic human and
rodent MCs. We demonstrate that AZIN2 localizes in the Vamp-8 positive, serotonin-containing subset of MC granules, but
not in tryptase-containing granules, as revealed by double immunofluorescence stainings. Furthermore, activation of MCs
induces rapid upregulation of AZIN2 expression and its redistribution, suggesting a role for AZIN2 in secretory granule
exocytosis. We also demonstrate that release of serotonin from activated MCs is polyamine-dependent whereas release of
histamine and b-hexosaminidase is not, indicating a granule subtype-specific function for polyamines.
Conclusions/Significance: The study reports for the first time the expression of AZIN2 outside the brain and testis, and
demonstrates the intracellular localization of endogenous AZIN2 in MCs. The granule subtype-specific expression and its
induction after MC activation suggest a role for AZIN2 as a local, in situ regulator of polyamine biosynthesis in association
with serotonin-containing granules of MCs. Furthermore, our data indicates a novel function for polyamines as selective
regulators of serotonin release from MCs.
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Introduction
Mast cells (MC) are highly versatile effector cells of the adaptive
and the innate immune system [1,2]. They are involved in a
variety of reactions ranging from acute allergic responses to
chronic inflammations, autoimmune disorders, atherosclerosis,
and cancer. Mammalian MCs are widely distributed in virtually all
vascularized tissues, and they are especially numerous in
anatomical sites directly interfacing with the external environment,
such as the skin, the airways, and the gastrointestinal tract. MCs
originate from bone marrow hematopoietic CD34+ progenitor
cells, which enter the circulation and migrate to peripheral tissues
where they ultimately reside. In tissues, MCs undergo differenti-
ation in the local cytokine microenvironment [3]. Mature MCs
thus represent a heterogenous population of cells with various
phenotypes depending on the anatomical location [4]. On their
surface, MCs express FceRI, a high-affinity IgE receptor, which
upon activation induces exocytosis of cytoplasmic secretory
granules, de novo synthesis of lipid-derived mediators, and release
of cytokines, chemokines, and growth factors [5]. Their mem-
brane-bound secretory granules contain a variety of preformed
mediators such as histamine, serotonin, and proteases such as
tryptase and chymase [6]. MCs are involved in various
pathological conditions including mastocytosis, which is a
spectrum of heterogenous and rare disorders characterized by
the pathological expansion and accumulation of MCs in tissues
[6]. The most prevalent form of mastocytosis is cutaneous
mastocytosis, in which MC infiltrations are found in skin.
Polyamines play a pivotal role in cell proliferation, apoptosis
and ion-channel gating. The cellular pools of polyamines are
under strict control; their uptake, biosynthesis, and catabolism are
regulated carefully [7]. In mammalian cells, ornithine decarbox-
ylase (ODC) catalyzes the rate-limiting step in polyamine
biosynthesis. Polyamine-induced antizymes (AZ) are the key
proteins that regulate the uptake of polyamines and the activity
of ODC [8]. Active ODC homodimers are converted to inactive
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AZ-bound ODC-monomers which are concomitantly degraded by
26S proteasome in a ubiquitin-independent manner [9]. So far,
three paralogs of mammalian AZ molecules have been described
[10,11]. AZ itself is under a multilevel control, achieved at protein
level by an ODC-homologous protein, namely antizyme inhibitor
(AZIN). AZIN binds AZ with higher affinity than ODC hence
inducing activation of ODC [12,13]. Two discrete AZINs are
expressed in mammalian cells, AZIN1 and AZIN2, both of which
counteract the functions of AZ thereby activating ODC and
depressing its degradation as well as enhancing polyamine uptake
[14–18]. All mammalian cells express the initially characterized
AZIN1, whereas AZIN2 expression has been reported to be most
abundant in brain and testis [19]. AZIN2 has been shown to have
lower affinity than AZIN1 towards AZs [18] but it is not known
why both AZINs are present in certain types of cells.
Upregulation of ODC activity and excess of cellular polyamines
are associated with rapidly dividing cells and neoplastic growth
[20]. However, much less attention has been paid to polyamine
functions in terminally differentiated, non-proliferating cells such
as MCs. It has nevertheless been shown that polyamines stimulate
exocytosis of MC granules by activating small GTP-binding
proteins [21], but the molecular mechanisms contributing to
granule exocytosis have remained unknown and the role of
polyamines in these cells is unsettled.
In the present study, we raised two rabbit antisera against
AZIN2 and immunostained sections of various human tissues with
them. We found that human skin MCs stained strongly positive for
AZIN2. We therefore decided to investigate the functional role of
AZIN2 and polyamines as potential mediators of MC activity. Our
data show that AZIN2 specifically localizes in the Vamp-8
positive, serotonin-containing granules and that activation of
ODC is selectively associated with the secretion of serotonin, but
not with the secretion of b-hexosaminidase (b-hex) or histamine
from human MCs. Our findings thus suggest that AZIN2 might




All of the chemicals used were obtained from Sigma (St. Louis,
MO, USA) unless stated otherwise. Oligonucleotides were
purchased from Oligomer (Helsinki, Finland), Lipofectamine
2000 was from Invitrogen (Carlsbad, CA, USA), the Complete
protease inhibitor cocktail was from Roche (Mannheim, Ger-
many), and D,L-a-difluoromethylornithine (DFMO) was from
Merrell Dow Research Institute (Cincinnati, OH, USA). The
following antibodies were used: mouse anti-FLAG M2 (Sigma-
Aldrich); mouse anti-human tryptase (Dako Cytomation, Glostrup,
Denmark); mouse anti-human Vamp-8 (Abnova, Taipei City,
Taiwan); mouse anti-human serotonin (Dako Cytomation); goat
anti-rabbit Alexa Fluor-680, donkey anti-rabbit Alexa Fluor-555,
and donkey anti-mouse Alexa Fluor-488 (all from Invitrogen
Molecular Probes, Eugen, OR, USA); donkey anti-mouse IRDye
800CW (LI-COR Biosciences, Lincoln, NE, USA).
Production and characterization of AZIN2 antibodies
Two polyclonal rabbit antisera were raised against synthetic
peptides STRDLLKELTLGASQATTDEVA (antiserum 2) and
STRDLLKELTLGASQATT (antiserum 3), corresponding to
amino acids 18–39 and 18–35 of AZIN2, respectively (Genbank
accession No. NP_443724). This N-terminal sequence has low
homology to ODC and AZIN1. Branched peptides were
synthesized with an automated multiple peptide synthesizer
(MultiPep; Intavis Bioanalytical Instruments AG, Cologne,
Germany) using Fmoc-chemistry and purified with HPLC using
a Supelco Discovery Biowide Pore C18 column (Supelco,
Bellefonte, PA, USA). The main peaks were collected, lyophilized
and used as antigens for immunizations. The antibodies were
produced at at the Viikki Laboratory Animal Centre, University of
Helsinki, Finland. All animals were handled in strict accordance
with good animal practice as defined by the relevant Finnish
animal welfare bodies, and the European Communities Council
directive (86/609/EEC). All animal work was approved by the
Animal Experiment Board of the State Provincial Office of
Southern Finland (Reference number HY176-02) in accordance
with national legislation. Whole sera from the immunized rabbits
were used for immunofluorescence stainings and negative controls
were prepared by substituting the primary antibodies with
preimmune rabbit sera.
The cDNAs encoding AZIN2, AZIN1, and ODC were
amplified from the corresponding constructs described earlier
[16] and they were subcloned into the p3xFLAG-CMV-10 vector
(Sigma-Aldrich). COS-7 cells were grown to 50% confluence and
transfected for 24 h with plasmids carrying FLAG-tagged AZIN2,
AZIN1, or ODC gene or an empty FLAG-vector using
Lipofectamine. The cells were lysed in buffer (50 mM Hepes,
pH 7.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM
EGTA, 100 mM NaF, 10 mM Na4P2O7 with protease inhibitors)
and the proteins were resolved by 12% SDS-PAGE and
transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA). The membranes were blocked with Odyssey blocking buffer
(LI-COR Biosciences), incubated with rabbit AZIN2 antiserum 2
or 3 (diluted 1:200) together with mouse anti-FLAG M2 antibody
(3 mg/ml), followed by donkey anti-mouse IRDye 800CW and
goat anti-rabbit Alexa Fluor-680 secondary antibodies (both
diluted 1:10,000). An Odyssey Infrared Imager (LI-COR Biosci-
ences) was used for visualization.
Tissue samples
Formalin-fixed, paraffin-embedded tissue samples of human
skin from patients diagnosed with cutaneous mastocytosis were
obtained from the Skin and Allergy Hospital, Helsinki University
Central Hospital, Helsinki, Finland.
Ethics Statement. This study was conducted according to
the principles expressed in the Declaration of Helsinki. All the
tissue samples were obtained with written informed consent from
the patients or their guardians. The tissue samples were used for
this study under approval of the institutional review board of
Haartman Institute, University of Helsinki.
Cell culture and activation
Rat basophilic leukemia cell line RBL-1 [22] was provided by
Dr. Tomas Mustelin (The Burnham Institute for Medical
Research, La Jolla, CA, USA) and the cells were cultured in
RPMI 1640 (Gibco BRL, Carlsbad, CA, USA) medium
supplemented with 10% (v/v) fetal calf serum (Gibco), 1 mM L-
glutamine (Fluka, Buchs, Switzerland), and antibiotics. All cell
cultures were maintained at 37uC in a humidified 5% CO2
atmosphere. The immature human leukemic MC line HMC-1
was provided by Dr. Joseph H. Butterfield (Mayo Clinic,
Rochester, NY, USA) and maintained as previously described
[23]. The human MC line LAD2, originating from a patient with
untreated MC sarcoma, was provided by Dr. Dean Metcalfe
(National Institute of Allergy and Infectious Disease, National
Institutes of Health, Bethesda, MD, USA) and cultured as
previously described [24]. Peripheral blood-derived, human
MCs were cultured in vitro as described earlier [25].
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The MCs were activated by 50 nM phorbol 12-myristate 13-
acetate (PMA) together with 1 mM (HMC-1) or 2 mM (RBL-1)
calcium ionophore A23187, or with 1 mg/ml of goat anti-human
IgE (primary human MCs). The cells were fixed or collected at the
indicated times and processed for immunocytochemical stainings
or quantitative real-time RT-PCR.
Immunohisto- and immunocytochemistry
Immunohistochemistry was carried out on 4–5 mm-thick skin
tissue sections from paraffin-embedded samples obtained from
patients with cutaneous mastocytosis (n = 15). The sections were
air-dried, deparaffinized in xylene, and rehydrated in a graded
ethanol series. Antigens were retrieved by microwaving sections in
10 mM citrate buffer (pH 6) for 20 min. Endogenous peroxidase
activity was quenched with 0.5% hydrogen peroxide in methanol
for 30 min, after which the sections were incubated with CAS-
block (Zymed Laboratories, Carlsbad, CA, USA) to block non-
specific reactivity. The AZIN2 antiserum 2 was diluted 1:180–
1:300, and AZIN2 antiserum 3 diluted 1:500–1:600 in DakoR-
EAL antibody diluent (Dako, Glostrup, Denmark) and incubated
overnight at +4uC. Bound antibodies were detected with an
avidin-biotin-horseradish peroxidase complex using a Vectastain
Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and
visualized by 3-amino-9-ethyl carbazole. The slides were finally
counterstained with hematoxylin and mounted. Negative controls
were prepared by substituting the primary antibody with the
corresponding preimmune rabbit serum.
For immunocytochemical staining, the MCs were cytocentri-
fuged with a Cytospin 3 centrifuge (ThermoShandon, Pittsburgh,
PA, USA) and fixed with MeOH. The staining was otherwise
carried out as specified above, except that AZIN2 antiserum 2 was
diluted 1:100 and AZIN2 antiserum 3 was diluted 1:300. Light
microscopy was performed with an Olympus BX51 microscope
(Olympus Optical, Tokyo, Japan) and images were acquired with
a Nikon Digital Sight DS-5M camera (Nikon Corporation, Tokyo,
Japan) using NIS-Elements F 2.30 software (Nikon Corporation).
The cells were photographed with a 406 objective (numeric
aperture 0.95) or a 1006 oil objective (numeric aperture 1.25).
For immunofluorescence staining, cytocentrifuged LAD2 and
RBL-1 cells were fixed with ice-cold methanol for 10 min, and
blocked with 10% human serum in PBS for 30 min. They were
then incubated with primary antibodies and species-appropriate
secondary antibodies conjugated with either Alexa Fluor-488 or
Alexa Fluor-555. Samples were mounted with Mowiol (Calbio-
chem, La Jolla, CA, USA) and image acquisition was performed
with a Leica TCS SP2 Laser Scanning system (Leica, Mannheim,
Germany) attached to a DM IRE-2 inverted microscope with a
406 oil objective (numeric aperture 1.25). The images were
processed with Leica LCS software and all the images were
assembled using Adobe Photoshop CS2 software.
Quantitative real-time RT-PCR
Total RNA of the cells was isolated using TRI Reagent RT
(Molecular Research Centre, Inc., Cincinnati, OH, USA). One
microgram of total RNA was reverse transcribed using a High
Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA,
USA) followed by PCR amplification using a Maxima SYBRGreen
qPCR Master Mix (Fermentas GMBH, St. Leon-Rot, Germany)
and a LightCycler II instrument (Roche Diagnostics, Mannheim,
Germany). The data were analyzed using Light Cycler software,
version 3.5 (Roche Diagnostics, Mannheim, Germany). The
expression level of AZIN2 was normalized against either human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or rat b-2-
microglobulin (b2 m). The following primers were used: human
AZIN2 (forward, 59-AGGGGCCAAAGTGAGATTTG-39; re-
verse, 59-CTTGGCAATGATGCTGACTG-39); rat AZIN2 (for-
ward, 59-GGGAGCCAAAGTGAGATTTG-39; reverse, 59-TGA-
AGGCTGACGTCACATAG-39); human GAPDH (forward, 59-
GGTGAAGGTCGGAGTCAAC-39; reverse, 59-CAAATGAGC-
CCCAGCCTTC-39); rat b2 m (forward, 59-ATGGCTCGCT-
CGGTGACC; reverse, 59-GTGAATTCAGTGTGAGCCAG-39).
The data are presented as mean 6 SD of triplicate samples.
Serotonin and b-hex release assay
LAD2 and in vitro generated human MCs were depleted of
polyamines by treatment with 2 mM DFMO, a specific inhibitor of
ODC, for 90 min to 4 days in IMDM-based medium containing
1% (v/v) dialyzed bovine serum. Cells were sensitized overnight
with 1 mg/ml of human myeloma IgE. Reconstitution of poly-
amines was accomplished by adding 0.5 mM putrescine to the cells
90 min prior to their activation. Degranulation of the sensitized
MCs was induced using anti-IgE for 0–30 min at 37uC, after which
the conditioned medium was collected and analyzed for serotonin
and b-hex. Serotonin was quantitated with commercial ELISA
(Labor Diagnostika Nord, Nordhorn, Germany) and b-hex was
analyzed using a colorimetric assay as previously described [26].
Briefly, 60 ml of supernatant was added in duplicates into a 96-well
plate and mixed with an equal volume of substrate solution (7.5 mM
p-nitrophenyl-N-acetyl-b-D-glucosaminide dissolved in 80 mM
citric acid, pH 4.5). The plate was thereafter incubated with a
gentle agitation for 60 min at 37uC. The reaction was then stopped
by addition of 120 ml of glycine (0.2 M, pH 10.7) to each well, and
the optical density at 405 nm and 490 nm was determined using a
plate reader (Wallac Victor3, Perkin-Elmer, Turku, Finland).
Results
Characterization of AZIN2 antisera
Antisera 2 and 3 raised against AZIN2 were evaluated for their
specificity to AZIN2 to exclude cross-reactivity with the homol-
ogous AZIN1 or with ODC. We transfected COS-7 cells with
AZIN2, AZIN1, or ODC tagged at the N-terminus with three
FLAG epitopes. Cell lysates were separated on SDS-PAGE and
immunoblotted with each of the two rabbit antisera together with
mouse anti-FLAG antibody. Simultaneous detection of two
antibodies was performed using an Odyssey Infrared Imager.
Antiserum 3 detected the same ,55 kDa band in AZIN2-FLAG
transfectants as in anti-FLAG without a backround (Figure 1A).
No cross-reactivity was observed with either ODC-FLAG or
AZIN1-FLAG, indicating specificity of the antiserum to AZIN2.
However, antiserum 2 failed to recognize any proteins in
immunoblotting, and was therefore retracted from this application
(data not shown). To further validate the antisera, COS-7 cells
were grown on coverslips, transfected with FLAG-tagged AZIN2,
AZIN1, or ODC for 24 h, and stained with mouse anti-FLAG
antibody together with either antiserum 2 or 3, and the
corresponding preimmune sera. The primary antibodies were
detected with fluorescent-labeled, species-selective secondary
antibodies, and visualized by confocal microscopy. Both antiserum
2 and antiserum 3 stained COS-7 cells successfully, and the signal
co-localized with FLAG in AZIN2-FLAG transfected cells
(Figure 1B), whereas no reactivity was seen in AZIN1-FLAG or
ODC-FLAG transfectants. Negative control stainings with rabbit
preimmune sera showed no positive signal (Figure 1B).
Expression of AZIN2 in cutaneous mastocytosis
Sections of human skin samples containing neoplastic infiltrates
of MCs were immunohistochemically stained with the two rabbit
Mast Cells Express AZIN2
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6858
Figure 1. Specificity testing of AZIN2 antisera. (A) Immunoblot from COS-7 cells transfected with plasmids carrying FLAG-tagged AZIN1, AZIN2,
or ODC gene or an empty FLAG-vector (Ctrl). An Odyssey Infrared Imager was used for simultaneous two-color detection of rabbit anti-AZIN2
(antiserum 3) and mouse anti-FLAG antibodies. The lowest panel represents merged blots, yellow indicating co-localization of anti-AZIN2 and anti-
FLAG. (B) Confocal laser scanning microscopy of COS-7 cells expressing one of the following genes: AZIN2-FLAG, AZIN1-FLAG, or ODC-FLAG. The cells
were stained with either AZIN2 antiserum 2 or 3 together with mouse anti-FLAG, followed by donkey anti-rabbit Alexa Fluor-555 and donkey anti-
mouse Alexa Fluor-488. AZIN2-FLAG-transfected cells were also stained with preimmune sera of the corresponding rabbits. In the merged images,
yellow indicates the co-localization. Bars represent 10 mm.
doi:10.1371/journal.pone.0006858.g001
Mast Cells Express AZIN2
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antibodies to AZIN2. Positive staining for AZIN2 was selectively
detected in the MCs of the affected skin areas, and also in scattered
normal skin MCs (Figure 2A). AZIN2 localized in the cytoplasm
with punctated, granular distribution (Figure 2A, inset). Both
rabbit antiserum 2 and 3 showed an identical staining pattern.
Preimmune sera from the corresponding rabbits did not stain
positively (Figure 2B).
Granular expression of AZIN2 in MCs
We next investigated the possible expression of AZIN2 in
human and murine MC lines. Immunocytochemical stainings
were performed on cytocentrifuged rat (RBL-1) and human
(HMC-1 and LAD2) MCs using the two rabbit antisera against
AZIN2 and the corresponding preimmune sera. To identify MC
granules, we also stained the MCs with monoclonal antibody to
tryptase. In all MC lines tested, AZIN2 and tryptase localized in
the cytoplasm with a granular pattern, revealing their presence in
the secretory granules (Figure 3A). AZIN2 was typically located in
the vicinity of the plasma membrane. The RBL-1 cells showed the
highest and LAD2 cells the lowest staining intensity for AZIN2.
Identical staining patterns were obtained with both antisera. In
addition, some nuclear AZIN2 was seen in both murine and
human MCs. All control stainings with the preimmune sera were
negative (Figure 3A). The expression of AZIN2 mRNA in these
MC lines was also verified by quantitative real-time PCR (data not
Figure 2. Immunohistochemical identification of AZIN2 protein
in human cutaneous mastocytosis. Human skin tissue sections
stained histochemically with either antiserum 3 to AZIN2 (A) or rabbit
preimmune serum (B). Original magnifications:6400 (A–B) and61000
(inset). Note the cytoplasmic granular-like staining pattern of AZIN2 in
the inset.
doi:10.1371/journal.pone.0006858.g002
Figure 3. Granular expression of AZIN2 in MC lines and
primary human MCs. (A) The MCs were immunostained with either
anti-tryptase, AZIN2 antiserum 3 (HMC-1, LAD2, and RBL-1), antiserum 2
(primary human MCs) or the corresponding rabbit preimmune sera
(Ctrl). Note the high variation of AZIN2 expression between individual
human MCs cultured for 12 weeks. Original magnification for all panels
61000. (B) Confocal laser scanning microscopy for AZIN2 with MC
granule markers tryptase and Vamp-8 in LAD2 cells, and serotonin in
RBL-1 cells. Double-immunofluorescence staining was performed using
rabbit antiserum 2 together with monoclonal antibody to tryptase,
mouse anti-Vamp-8 or monoclonal antibody to serotonin, followed by
Alexa Fluor-555 conjugated donkey anti-rabbit and Alexa Fluor-488
conjugated donkey anti-mouse IgGs. The right panel represents
merged images; yellow indicates the co-localization. Bars represent
10 mm.
doi:10.1371/journal.pone.0006858.g003
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shown). Staining of HMC-1 and LAD2 cells for tryptase revealed
greater amounts of tryptase-positive granules than of AZIN2-
positive granules (Figure 3A). Since we used a human tryptase
antibody that did not cross-react with murine tryptase, we were
unable to perform staining for tryptase in RBL-1 cells.
The MC lines used in the study originated from neoplasias. We
repeated the immunocytochemical stainings on benign, primary
human MCs that had been differentiated in vitro for 5 and 12 weeks
from adult peripheral blood CD34+ progenitor cells. Immature 5-
week-old primary human MCs expressed AZIN2 uniformly
throughout the cytoplasm in a granular pattern (Figure 3A),
similar to that seen in the MC lines. A similar granular distribution
of AZIN2 was also seen in the 12-week-old mature human MCs,
but with considerable variation in the level of AZIN2 expression
among the individual cells. It was also notable that the AZIN2-
positive granules in the primary MCs were more evenly distributed
throughout the cytoplasm, and not clustered in the periphery as in
the MC lines. The primary human MCs also contained more of
tryptase-positive granules than AZIN2-positive granules
(Figure 3A). Furthermore, variable amounts of tryptase were
observed in the mature human MCs, similar to what was seen in
AZIN2, suggesting that extended differentiation in vitro induces
heterogeneity in the MCs.
We performed double immunofluorescence stainings to char-
acterize further the AZIN2-containing granules. Simultaneous
staining of LAD2 cells with antibodies to AZIN2 and tryptase did
not reveal any co-distribution, indicating that tryptase and AZIN2
localize in distinct granules. Co-staining of AZIN2 and serotonin
showed that all serotonin-containing granules were also positive
for AZIN2 in RBL-1 cells. In the LAD2 cells, AZIN2 expression
overlapped partially with Vamp-8, especially in the peripheral
cytoplasm, close to the plasma membrane (Figure 3B). Vamp-8
has been shown to localize specifically in serotonin-containing MC
granules [27]. This finding, together with the present data, shows
that AZIN2 is selectively expressed in the Vamp-8 positive,
serotonin-containing subset of MC granules, suggesting a granule
subset-specific function.
AZIN2 expression is coupled to activation of MCs
Next we examined whether the expression of AZIN2 is coupled
to the activation of MCs. The expression of AZIN2 mRNA was
quantified by real-time PCR, and the distribution of AZIN2
positive granules was studied by immuocytochemistry in RBL-1
and HMC-1 cells, after the cells had been activated with PMA and
the calcium ionophore A23187. After 15 min of activation, the
mRNA of AZIN2 was elevated in both cell lines; after 30 min the
mRNA levels had more than doubled as compared to untreated
control cells (Figure 4A–B). Thereafter, AZIN2 mRNA expression
declined, and after 180 min the RBL-1 cells expressed even less
AZIN2 than the untreated cells (Figure 4A). A similar decrease in
the level of AZIN2 mRNA was also seen in HMC-1 cells after
180 min of activation (Figure 4B). This rapid fluctuation of AZIN2
mRNA suggests a functional relation of AZIN2 transcription with
MC activation.
Immunocytochemistry of activated RBL-1 and HMC-1 cells
revealed changes in AZIN2 staining intensity and also in the
distribution of AZIN2-positive granules (Figure 4A–B). In
untreated RBL-1 and HMC-1 cells, AZIN2 was detected in
sparse, dispersed cytoplasmic granules and also in the nucleus.
After 15 min of activation, the staining intensity for AZIN2 was
increased in both the cytoplasm and the nucleus. AZIN2-positive
granules relocated to the peripheral areas of the cells. The staining
intensity for AZIN2 peaked after 30 min of activation, and
translocation of AZIN2-positive granules to the vicinity of the
plasma membrane became more prominent. After 60 min of
activation, AZIN2 was seen only on the cell membrane of a few
RBL-1 cells (Figure 4A), whereas the HMC-1 cells expressed
AZIN2 solely in the nucleus (Figure 4B). These activation-induced
rapid changes in the expression level and intracellular distribution
suggest that AZIN2 plays a role in the exocytosis of MC granules.
Polyamine depletion delays serotonin release from MCs
Given that AZIN2 is an activator of ODC, the rate-limiting
enzyme of polyamine biosynthesis, we next investigated the impact
of polyamines on MC degranulation. Primary human MCs and
LAD2 cells were cultivated in polyamine-free medium and treated
with DFMO to block ODC activity. Treatment with DFMO
inhibited the IgE-triggered release of serotonin from both primary
human MCs and LAD2 cells (Figure 5A–B). Furthermore, this
inhibitory effect of DFMO was reversed by the addition of
putrescine to the cells. In contrast, treatment with DFMO with or
without putrescine, had no impact on b-hex (Figure 5C–D) or
histamine release (data not shown). We extended the duration of
DFMO treatment from 90 min to 4 days prior to activation of the
cells. The inhibitory effect on induced serotonin release persisted,
whereas the release of b-hex and histamine remained unchanged,
suggesting that the basal level of polyamines is low in resting MCs.
All in all, these results indicate that polyamines selectively regulate
the release of serotonin from MCs without affecting the release of
other granular MC mediators. Our serotonin release assay also
showed that the content of serotonin was higher in primary human
MCs than in LAD2 cells (Figure 5A–B).
Discussion
AZINs function as inducers of ODC activity in the biosynthesis
and uptake of polyamines. Of the AZINs, AZIN1 is ubiquitously
expressed and found in all mammalian cells. The other isoform,
AZIN2, which we originally discovered (then called ODCp), has a
selective distribution, and was previously reported to be present
only in the brain and testis [19]. In the present study, we report a
robust expression of AZIN2 in normal and neoplastic MCs.
In our original paper on human AZIN2 [19], we reported the
possibility of at least eight different splicing variants for this protein.
The biological significance of the alternative splicing and the
amount of in vivo translated splicing variants of AZIN2 remains to be
established. The likely existence of splicing variants of AZIN2 may
nevertheless have an impact on its reactivity with antibodies. We
used two rabbit antisera raised against peptides representing the
most unique part of AZIN2. The peptide used as immunogen for
antiserum 2 was derived from a sequence that spans an intron-exon
boundary known to involve multiple splicing, beginning from exon
1 and ending in exon 3, but excluding exon 2, which is not included
in the splicing variants 1–7 [19]. The second peptide used to
produce antiserum 3 was derived from exon 1, present in all
putative splicing variants of AZIN2. As seen in Figures 3 and 4, the
staining intensity of AZIN2 varied slightly between the two antisera,
antiserum 3 producing stronger stainings than antiserum 2. This
may be due to alternative splicing of AZIN2. In spite of the
variations in the staining intensities, both antiserum 2 and 3 yielded
highly similar results regarding the staining patterns of MC
granules, while only antiserum 3 was functional in immunoblotting.
Due to the high degree of structural homology between ODC and
AZINs, earlier studies with antisera raised against the whole ODC
protein may need to be reinterpreted, due to the potential cross-
reactivity with AZIN1 and AZIN2.
Immunocytochemical stainings for AZIN2 with antisera 2 and 3
revealed a granular distribution mainly in the cytoplasm of
Mast Cells Express AZIN2
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primary human MCs and the MC lines. Immunohistochemistry of
normal and neoplastic tissue MCs showed a similar granular
pattern. Immature human primary MCs obtained after 5 weeks of
culture displayed a homogenous expression of AZIN2-positive
granules, whereas 12-week-old mature MCs varied considerably in
the intracellular expression of AZIN2-positive granules. This
suggests that the terminal differentiation of MCs in vitro leads to the
establishment of a subpopulation of MCs with variable expression
of AZIN2. In addition to the cytoplasmic granules, there were
variable amounts of AZIN2 in the nuclei of MCs. Especially
antiserum 3 detected frequently nuclear AZIN2 in all the MC lines
used regardless of the staining method. Since ODC, AZs, and
polyamines have been shown to localize also in the nuclei of
different mammalian cells [28–30], the nuclear staining for AZIN2
was not entirely unexpected, although its functional relevance
remains unclear. ODC has a rapid turnover in normal cells, and
AZIN1 is also known for its short half-life [31]. We found a
promptly upregulated expression of AZIN2 mRNA upon
activation of MCs with PMA and the calcium ionophore
A23187. Although the half-life of AZIN2 remains to be
determined, our findings suggest a rapid turnover of AZIN2
similar to that of its homologues ODC and AZIN1.
We co-stained the AZIN2-containing MC granules with
tryptase, a robust marker of classical secretory granules in MCs,
Figure 4. Upregulation and redistribution of AZIN2 in MCs during activation. RBL-1 (A) and HMC-1 (B) cells were activated with PMA and
A23187 for the times indicated. After activation, the cells were either immunostained for AZIN2 (antiserum 2) or harvested for quantitative real-time
PCR analysis of AZIN2. Relative mRNA levels are expressed as the ratio of AZIN2 mRNA level to that of either rat b-2-microglobulin (b2 m) or human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Original magnification of all immunostainings:6400.
doi:10.1371/journal.pone.0006858.g004
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in order to further characterize the granules. The staining revealed
a distribution of AZIN2 distinct from that of tryptase. Instead, we
observed a co-localization of AZIN2 and the vesicle-associated v-
SNARE protein Vamp-8 (also known as endobrevin). Moreover,
the granular distribution of serotonin overlapped with that of
AZIN2. Our results thus support the existence of distinct subsets of
MC granules, demonstrated earlier by Puri and Roche [27]. The
authors reported an association between subsets of MC granules
and specific SNARE proteins, and found that a majority of the
serotonin-containing MC granules were Vamp-8-positive. Fur-
thermore, the authors found that serotonin and histamine were
present in two distinct granule subtypes, and described that the
secretion of serotonin was impaired, but not that of histamine, in
MCs of Vamp-8-deficient mice. Differential release of MC
mediators further supports the existence of separate granule
populations. Already in 1982, Theoharides et al. [32] found
evidence for differential release of MC mediators from the
secretory granules. The authors showed that amitriptylin blocks
the exocytotic release of histamine from activated MCs without
affecting serotonin release. Here, we show that in the absence of
external polyamines, the treatment of MCs with DFMO, that
specifically blocks the activity of ODC, selectively impairs the
release of serotonin without affecting the exocytosis of b-hex or
histamine. The finding is in agreement with previous reports
indicating differential release of MC mediators. We also
demonstrate that addition of external putrescine restores the
secretion of serotonin, indicating that polyamines are key
mediators of serotonin release from MCs.
The expression of AZIN2 in only a few tissue and cell types
suggests a specific regulatory role in polyamine homeostasis. In MCs,
the induction of AZIN2 expression together with the granule subtype-
specific distribution suggests that AZIN2 is likely to mediate ODC
activation in situ in serotonin-containing granules during MC
activation. Since we also provide evidence indicating that secretion
of serotonin from MCs following IgE-mediated stimulation is
polyamine-dependent, it can be speculated that AZIN2 specifically
regulates this process. To further study this potential role of AZIN2,
we attempted to knock down AZIN2 by siRNA-mediated RNA
interference in MCs. This approach was, however, hampered by the
fact that mature MCs turned out to be very difficult to transfect by
conventional means. Thus further studies are needed to directly
define the role of AZIN2 in relation to serotonin secretion fromMCs.
Figure 5. Polyamine depletion inhibits serotonin release from MCs. LAD2 (A, C) and primary human MCs (B, D) were cultured in polyamine-
free medium and sensitized overnight with human myeloma IgE. Before activation, the cells were and treated with 2 mM DFMO as described in
Materials and Methods, and subsequently activated with anti-IgE for the indicated times; and the conditioned medium was analyzed for serotonin (A–
B) and b-hex (C–D) release. Symbols represent treatment of MCs: anti-IgE only (%), anti-IgE + 2 mM DFMO + 0.5 mM putrescine (&), anti-IgE + 2 mM
DFMO (#), non-stimulated (N ).
doi:10.1371/journal.pone.0006858.g005
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The exact molecular mechanisms by which polyamines
selectively regulate the secretion of serotonin from activated
MCs remain to be elucidated. However, there are a couple of
potential mechanisms that could be hypothesized. Polyamines
regulate the gating of various ion channels including calcium
channels, enhancing Ca2+ influx in various types of cells [33–37].
Activation of MCs with ensuing granule exocytosis is known to
depend strongly on Ca2+ signaling [5]. Therefore, AZIN2 could
participate in local activation of ODC sequestered to AZ, and
provoke the production of polyamines in situ, which would
consequently enhance Ca2+ mobilization. On the other hand,
granule exocytosis from activated MCs is regulated by small GTP-
binding proteins of the Rho family. Price et al. [38] reported that
introduction of constitutively active mutants of RhoA and Rac to
permeabilized MCs induced enhanced exocytosis upon triggering,
whereas inactivation of RhoA by pretreatment with the Clostridium
botulinum C3 transferase abolished the effect. Although the RhoA
family proteins are the major modulators of actin cytoskeleton
dynamics, their impact on MC exocytosis is not directly linked to
the regulatory effects on actin polymerization [38]. We have
recently reported that RhoA is activated in vivo by transglutamin-
ase-2-mediated polyamination in an ODC-dependent fashion
[39]. Given this, it is appealing to speculate that AZIN2-induced
local activation of ODC and polyamine biosynthesis may lead to in
situ polyamination and activation of RhoA, which subsequently
governs the intracellular transport of MC granules.
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